Genmab — November 2023
-
nejm -Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
https://www.nejm.org/doi/full/10.1056/NEJMoa2306441 -
-
Yes you are right. Majestec 1 was mono. In Majestec 2: the overall response rate (ORR) was 93.5 percent.1 Among all patients in the trial, VGPRs or better were achieved by 90.3 percent of patients, and 54.8 percent of patients achieved a complete response (CR) or better.
-
-
Tisotumab Vedotin Survival Data in Cervical Cancer Are “Game-Changing" https://www.cancernetwork.com/view/tisotumab-vedotin-survival-data-in-cervical-cancer-are-game-changing-
-
Trial investigator Brian Slomovitz, MD, Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center, discusses results from the global, randomized, open-label Phase 3 innovaTV 301 trial
https://www.youtube.com/watch?v=HIZzLVIh15c -
Det lyder umiddelbart rigtig godt med Tiso, det er en frygtelig sygdom!
-
https://finance.yahoo.com/news/abbvie-acquire-immunogen-including-flagship-123000719.html ligner +80-90% i præmium
-
Ingen godkendte stoffer, men et på vej https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-european-medicines-agency-acceptance
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind